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The 5-hydroxytryptamine (5-HT) receptor family mediates the
effects of several drugs highly effective in migraine primarily by
activating 5-HT1B, 5-HT1D, and 5-HT1F receptors. Ergotamine,
dihydroergotamine, and methysergide, as well as the “triptan”
sumatriptan, are all agonists for these receptors. The receptor
profile and degree of selectivity of these four drugs differ, which is
reflected by their side effects that limit their use in the acute and
prophylactic treatment of migraine. The acute antimigraine efficacy
of these remedies is very much dependent on the formulation used
where, in general, parenteral formulations are more effective in
reliving the symptoms of a migraine attack.
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Serotonin (5-hydroxytryptamine; 5-HT) is monoamine that
has been found to play a fundamental role in the regulation of
physiologic and pathophysiologic processes.1 The serotonin
receptor family is currently grouped into 7 subfamilies (5-HT1 to
5-HT7) and 14 receptor subtypes2 that have different anatomic
locations. All the receptors, with the exception of the 5-HT3
receptor, belong to the super family of 7 transmembrane domain
G-protein-linked receptors.3 The 5-HT receptor family mediates
the effects of several drugs highly effective in migraine primarily
by activating 5-HT1B, 5-HT1D, and 5-HT1F receptors.4-7 The
ergot alkaloids, also referred to as “ergots,” ergotamine, dihydro-
ergotamine (DHE), and methysergide, as well as the “triptan”
sumatriptan, are all agonists for these receptors.8,9 Ergotamine
and DHE were the first specific acute antimigraine drugs for
several decades until the advent of the triptans10 that are also used
in the acute treatment of migraine. In contrast, methysergide is
used as a prophylactic drug to prevent migraine attacks.9
Ergotamine and DHE were originally developed as sym-
patholytics, but it was later concluded that their therapeutic
efficacy was probably mediated by vasoconstriction of cranial
blood vessels (for review, see Müller-Schweinitzer11). As expected
from this pharmacologic profile, their most important pharma-
cologic effect is arterial constriction.11,12 Indeed, at therapeutic
concentrations, ergotamine and DHE induce a potent vasocon-
striction in the external carotid (extracranial) vascular bed of
anesthetized dogs mainly by activation of a-adrenoceptors and
5-HT (mainly 5-HT1B) receptors.13,14 Whereas both ergotamine
and DHE constrict the cranial vascular bed, there is a difference
in their capacity to constrict peripheral blood vessels. Ergotamine
induces contraction of peripheral arteries, including the pulmo-
nary,15 cerebral,11 temporal,16 and coronary17 arteries. In contrast,
DHE is a more potent constrictor of venous capacitance vessels
than of arteries.18 In humans, blood pressure is transiently
increased for about 3 hours after parenteral therapeutic doses of
ergotamine and DHE,19,20 which is likely caused by an increased
peripheral resistance.21 In contrast, a much longer lasting con-
strictor effect on peripheral arteries (ergotamine) or veins (DHE)
is induced. This is most likely caused by a slow diffusion from the
receptor biophase;22 the effects last much longer than expected
from the plasma concentrations.17,23,24 Thus, overall, based on
in vitro, in vivo animal data and human clinical research, both
ergotamine and DHE have the propensity to induce potent and
long-lasting cardiovascular side effects, although the side
effect profile of DHE is more favorable compared with that of
ergotamine.25,26
Besides a vascular mode of action, which was originally
believed to be the exclusive mechanism the antimigraine efficacy
of ergot alkaloids, the neuronal properties of these compounds
most probably also contribute to their clinical effects. The neu-
ronal activity is probably mediated via the agonist activity at
5-HT1B, 5-HT1D, and 5-HT1F receptors on trigeminal nerve
terminals resulting in the inhibition of the neuronal release of
vasoactive peptides and preventing vasodilatation in migraine.27
Methysergide does also have antagonistic properties on 5-HT2
receptors, which were originally considered to underlie its thera-
peutic efficacy in migraine. However, given the fact that other
potent 5-HT2 receptor antagonists, such as mianserin, sergolex-
ole, and ketanserin, are ineffective in the treatment of migraine,
it is highly improbable that 5-HT2 receptor antagonism plays a
major role in migraine prophylaxis.28
In contrast with the ergot alkaloids, sumatriptan does not
display affinity for the dopamine and noradrenaline receptors,
and is thus pharmacologically more selective.29 In lower thera-
peutically relevant concentrations, ergotamine and DHE act as
agonists at a-adrenoceptors, 5-HT (particularly 5-HT1B/1D), and
dopamine D2 receptors.8 Moreover, DHE and sumatriptan do
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not cause the dubious side effect of fibrotic changes, like retro-
peritoneal fibrosis, which is mediated by 5-HT2B receptors and
has been reported for both methysergide and ergotamine.30,31
Furthermore, the pharmacokinetic properties of each of these
drugs can be markedly affected by its formulation and thus, the
route of administration.32 Although oral formulations are the
most popular among patients, they are not the most appropriate
route of administration for drug delivery during the migraine
attack. Because of gastrointestinal dysmotility, the intestinal
absorption of any triptan given orally may be impaired, and
treatment effects become inconsistent.33 Therefore, more consid-
eration should be given to prescribing triptans in a non-oral
formulation (injection, nasal spray, or suppository). Parenteral
administration of a triptan is more likely to provide relief of
symptoms, even when it is used later in the course of the migraine
attack.34
Migraine headache is a complex of symptoms that present
clinically as discrete episodes of severe headache with associated
features such as phonophobia, photophobia, nausea, and
emesis. Migraine can be broadly characterized as headache pain
with associated disturbances in sensory sensitivity.35 The specific
cause of migraine headache is still unknown, although a
number of recently discovered genetic factors seem to be
important in some patients.36 These abnormalities involve neu-
ronal ion channels that could regulate central nervous system
(CNS) excitability in response to migraine trigger factors.35,36
The trigeminal sensory nerves arise from neurons in the
trigeminal ganglia that have pseudo-unipolar morphology.
Nerve fibers arising from the trigeminal neurons innervate
cranial blood vessels in the periphery.37 Trigeminal fibers rel-
evant to nociception project centrally behind the blood brain
barrier by way of the descending spinal trigeminal tract and
terminate in the spinal trigeminal nucleus in the medulla.38,39
Because of somatotopic organization, sensory fibers that inner-
vate the dura mater terminate within the most caudal region of
the nucleus (ie, trigeminal nucleus caudalis). Thus, trigeminal
sensory neurons provide a pathway to convey nociceptive infor-
mation from blood vessels in the meninges into the CNS. This
system is referred to as the trigeminovascular system.40 When
activated, perivascular sensory nerves release vasoactive neu-
ropeptides (eg, substance P, calcitonin gene-related peptide,
neurokinin A).40-44 Peptide release from these fibers can result in
the transmission of nociceptive impulses to second-order
sensory neurons in the trigeminal nucleus caudalis that then
relay this information to higher CNS centers.45 Central pain
transmission activates CNS autonomic nuclei in the brainstem
and other ascending nervous pathways, and this may, in turn,
contribute to the production of the symptoms that are associ-
ated with migraine, namely nausea, emesis, phonophobia, and
photophobia.46
5-HT1 agonists have 4 potential mechanisms of
action:4,5,47-50
1. Stimulation of the 5-HT1B receptor on cranial
vascular smooth muscle is hypothesized to increase the
tonus of the vessel wall, which counteracts the pulse syn-
chronic activation of stretch receptors that may be respon-
sible for throbbing headache.
2. Stimulation of the 5-HT1D receptors on trigeminal nerve
terminals innervating the meningeal blood vessels to block
the release of neuropeptides that are theorized to induce
pain/inflammation.
3. Stimulation of central 5-HT1B/1D/1F receptors in the trigemi-
nal nucleus caudalis to impair the transmission of afferent
signaling from the first-order to the second-order trigemi-
nal sensory neurons and preventing wind-up (temporal
summation) in the trigeminal sensory processing and long-
lasting central sensitization (pain hypersensitivity).
4. Stimulation of the 5-HT1B/1D receptors in the ventropos-
teromedial (VPM) thalamus to inhibit the process of noci-
ceptive input from to the second-order to the third-order
trigeminal sensory neurons in VPM thalamus.
Which mechanism is the most important is as yet unclear.
These actions inhibit the effects of activated nociceptive trigemi-
nal afferents and, in this way, control the symptoms induced
during an acute attacks of migraine.
The main objective with this review is to enlighten the phar-
macodynamic and pharmacokinetic properties of ergotamine,
DHE, sumatriptan, and methysergide in relation to existing for-
mulations and their use in acute and prophylactic treatment of
migraine.
Dihydroergotamine-Pharmacodynamic and Pharmacokinetic
Properties
DHE (Fig. 1) displays affinity for a wide variety of receptors
including those for 5-HT (serotonin), dopamine, and noradrena-
line (see Table 1 and Müller-Schweinitzer11). The absolute bio-
availability of intramuscular (i.m.) DHE is 100%. The absolute
bioavailability of DHE following intranasal (i.n.) administration,
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Fig 1.—Dihydroergotamine. Chemical structure: The chemical name
of dihydroergotamine is ergotaman-3’,6’,18-trione,9,10-dihydro-12’-
hydroxy-2’-methyl-5’-(phenylmethyl)-(5’a)-monomethanesulfonate.
Its molecular weight is 583.68, and its empirical formula is
C33H37N5O5·CH4O3S (mesylate salt).
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which avoids first-pass hepatic metabolism, is approximately
40%. Peak plasma levels occur approximately 1-2 minutes after
i.v. administration, 24 minutes after i.m. administration and
30-60 minutes after i.n. administration. Bioavailability after oral
administration is less than 1% (for review, see Saper and Silber-
stein25). DHE is rapidly and extensively metabolized in the liver.
Only 6-7% of an i.m. dose is excreted in the urine. The major
route of elimination is the feces following biliary excretion of
unchanged drug and metabolites. DHE has many metabolites;
only those that retain the essential ring structures of the ergot
alkaloids (the ergoline ring and the peptide side chain) are active.
The major metabolite is 8’-OH DHE that is present at a con-
centration 5 to 7 times greater than that of DHE. The pharma-
cologic effects of the active metabolites are qualitatively similar to
those of the parent compound. DHE is eliminated in a biphasic
manner, with mean half-lives of approximately 0.7-1 and 10-13
hours.
Because of slow diffusion from the receptor biophase, the
effects of DHE, as well as for ergotamine, last far longer than can
be expected from plasma concentrations. For this reason, the
pharmacokinetic data of ergotamine and DHE available cannot
be used to predict the biologic response.
An interaction with erythromycin may dramatically increase
the oral bioavailability of ergotamine and DHE.53 Because the
same cytochrome P450 enzyme CYP3A4 metabolizes a number
of other drugs, including bromocriptine, dexamethasone, ethi-
nyloestradiol, ketoconazole, nifedipine, omeprazole, and vera-
pamil, this interaction may extend to these drugs as well.54
Formulations
DHE is available as subcutaneous (1 mg), i.m. (1 mg),
intravenous (i.v.) (1 mg), and intranasal (2 mg) formulations.
Recently, clinical trials have been performed with MAP0004,
an orally inhaled formulation of DHE, which reaches
efficacy against migraine with a lower Cmax than observed after i.v.
administration.55
Adverse events
DHE may increase the risk of dangerously decreased blood flow
to the brain, heart, or extremities. In rare but severe cases, gan-
grene or other serious problems can result.
Contraindications
Peripheral vascular disease or poor circulation, arteriosclerosis,
hypertension, angina (history of heart attack, silent ischemia),
liver disease, kidney disease, and serious infections.
Pregnancy/nursing
DHE can be very harmful if used during pregnancy. DHE can
induce uterine contractions, and it can restrict blood flow to the
fetus. Patients should not use DHE if they are pregnant or could
become pregnant during treatment. In a Swedish registry,
however, there was no increased risk for congenital malforma-
tions after maternal use of DHE or ergotamine.61 DHE passes
into breast milk and may be harmful to a nursing infant. DHE
may also decrease milk production. Thus, patients should not use
DHE during lactation.
Ergotamine-Pharmacodynamic and Pharmacokinetic
Properties
Similar to DHE, ergotamine displays affinity for a wide variety of
receptors including those for 5-HT (serotonin), dopamine, and
noradrenaline (see Table 1 and Müller-Schweinitzer11). Oral
absorption of ergotamine (Fig. 2) is 60-70%, and the concurrent
administration of caffeine improves both the rate and extent of
absorption. However, because of high first-pass metabolism,
ergotamine has a very low oral and rectal bioavailability. If com-
pared with its i.v. bioavailability (100%), oral bioavailability of
ergotamine is <1%, rectal bioavailability of ergotamine is 1–3%,
and i.m. bioavailability of ergotamine is 47%.56,57 Ergotamine is
metabolized in the liver by largely undefined pathways, and 90%
of the metabolites are excreted in the low oral bioavailability (less
than 1%) because of incomplete drug passage across the gas-
trointestinal mucosa and a high first-pass metabolism.57,58 The
absolute bioavailability of i.m. ergotamine is 100%.
Table 1.—Pharmacological Activity of Dihydroergotamine (DHE),
Ergotamine, Sumatriptan, and Methysergide, Respectively, at
Animal or Human Monoaminergic Receptors. Values for DHE,
Ergotamine, and Sumatriptan are Affinity IC50 (nM).8,58
Receptor DHE Ergotamine Sumatriptan Methysergide
5-HT1A +++ +++ ++ ++*
5-HT1B +++ +++ +++ ++*
5-HT1D +++ +++ +++ ++*
5-HT1E + + + N.D.
5-HT1F + + ++ N.D.
5-HT2A ++ N.D. 0 +*
5-HT2C +++ N.D. 0 N.D.
5-HT3 0 0 0 N.D.
5-HT4 + + 0 N.D.
a1a ++ ++ 0 0**
a1b ++ ++ 0 N.D.
a2a +++ N.D. 0 0**
a2b +++ N.D. 0 N.D.
a2c +++ N.D. 0 N.D.
b1 0 N.D. 0 N.D.
b2 0 N.D. 0 N.D.
b3 + N.D. 0 N.D.
D2 +++ +++ 0 +**
D3 ++ +++ 0 N.D.
D4 ++ +++ 0 N.D.
Values for methysergide refer to *KD values59 and **Ki values,60 respec-
tively. Values for N.D. = not determined. +++, ++, + and 0 indicate
IC50 affinities (nM) <5 nM, >5 to <50 nM. >50 to <1500 nM, and
>1500 nM, respectively.
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Formulations
Ergotamine is available in combination with caffeine as a con-
ventional tablet form (0.5 mg and 50 mg, respectively) and in
some countries it is also available in a suppository form (1 mg
and 100 mg, respectively).
Adverse events
Ergotamine may increase the risk of dangerously decreased blood
flow to the brain, heart, or extremities. In rare but severe cases,
gangrene or other serious problems can result. Commonly
reported adverse events are nausea; vomiting; weakness; or cold-
ness, numbness, or pain in the hands, feet, arms, or legs.
Contraindications
Peripheral vascular disease or poor circulation, arteriosclerosis,
hypertension, angina (history of heart attack, silent ischemia),
liver disease, kidney disease, and serious infections.
Pregnancy/nursing
The use of ergotamine during pregnancy is associated with a
shorter mean gestational age and smaller mean birth weight, in
addition to a higher rate of low birthweight newborns and
preterm births.59 These associations might be explained by the
uterotonic effects of ergotamine, as well as its vasoconstrictive
effect on the placenta and the umbilical cord. Ergotamine passes
into breast milk and may be harmful to a nursing infant. Thus,
ergotamine should not be used during pregnancy or lactation
(Fig. 3).
Sumatriptan-Pharmacodynamic and Pharmacokinetic
Properties
Sumatriptan (Fig. 3) is a potent, selective 5-HT1B/1D/1F receptor
agonist, having high affinity for human 5-HT1B and 5-HT1D
receptors, with a slightly lower affinity at 5-HT1F receptors (see
Table 1).47,60 It displays only a weak affinity at 5-HT1A and
5-HT1E receptors (Table 1) At clinically relevant doses, concen-
trations of sumatriptan achieved doses (Cmax of 54-77 ng/mL,
equivalent to 0.1-0.2 mM) are unlikely to be within the range
required to activate 5-HT1A or 5-HT1E receptors. Sumatriptan
has no significant activity at other 5-HT receptor types (5-HT2
to 5-HT7) or at a wide range of other non-5-HT receptors and
ion channels (eg, adrenergic, dopaminergic, and histamine recep-
tors) (see Table 1). Recent research has focused on the relative
importance of 5-HT1B, 5-HT1D, and 5-HT1F receptors in medi-
ating the clinical efficacy of sumatriptan. While a selective
5-HT1D receptor agonist was not effective in the treatment of
migraine,62 the selective 5-HT1F agonist lasmiditan is effective
against migraine.63
Oral absorption of sumatriptan may be influenced by variable
gastric emptying and small bowel transit. Multiple peaking
occurs with a tmax of 2 hours. Oral bioavailability is low (14%),
and results from incomplete absorption and first-pass hepatic
metabolism.47 Protein binding ranges from 14% to 21%.
Approximately 80% of a dose is hepatically metabolized.
Metabolism produces an inactive metabolite and its glucuronide
conjugate. Renal clearance is believed to be by tubular secretion
as well as glomerular filtration. About 60% is excreted renally,
primarily as the indole acetic acid metabolite with approximately
3% as unchanged drug. The remaining 40% is excreted in the
feces. The mean terminal half-life is about 2 hours.
Other pharmacokinetic parameters for the various formula-
tions of sumatriptan are summarized in Table 2. Of the long-
standing sumatriptan formulations, the injection is most rapidly
absorbed (time to maximum concentration [tmax] = 12 minutes),
followed by the nasal spray (tmax = 1-1.5 hours) and the supposi-
tories (tmax 1.5 hours), followed by the conventional tablet
(tmax = 2 hours). Consistent with this pharmaceutic profile, the
pharmacokinetic parameters measured 0-2 hours after dosing
suggest slightly faster absorption, on average, of the fast-
disintegrating/rapid-release tablet compared with the conven-
tional sumatriptan tablet.
Formulations
Sumatriptan was initially introduced in an injectable formulation
(6 mg), which was soon followed in many countries by the intro-
duction of a conventional tablet form (available in 25-mg,
50-mg, and 100-mg strengths depending on the country) and a
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Fig 2.—Ergotamine. Chemical structure: The chemical name of
ergotamine is (6aR,9R)-N-( (2R,5S,10aS,10bS)- 5-benzyl-10b-
hydroxy-2-methyl- 3,6-dioxooctahydro-2H-oxazolo[3,2-a] pyrrolo
[2,1-c]pyrazin-2-yl) -7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]
quinoline-9-carboxamide. Molecular weight is 581.66, and its empirical
formula is C33H35N5O5.
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Fig 3.—Sumatriptan. Chemical structure: The chemical name of
sumatriptan (Imigran® or Imitrex™) is 3-[2-(dimethylamino)ethyl]-N-
methyl-1H-indole-5-methanesulfonamide. Its empirical formula is
C14H21N3O2S, and its molecular weight is 295.4. A white to off-white
powder, sumatriptan is soluble in water and saline.
Headache Currents
710 | Headache | April 2012
nasal spray form (available in 5-mg, 10-mg, and 20-mg strengths
depending on the country). In some countries, sumatriptan is
also available in a suppository form (25 mg). The latest sumatrip-
tan formulation, a fast-disintegrating/rapid-release oral tablet,
has recently been introduced into clinical practice.64 The fast-
disintegrating/rapid-release tablet was developed in response to
the consistent findings that patients prefer tablet forms of
migraine medication to other forms.
Adverse events
The most common adverse event with sumatriptan injection is
burning or stinging at the injection site, which was reported in
approximately 60% of patients in clinical trials. Patients may also
experience warm/hot sensation, tightness, tingling, flushing, and
feelings of heaviness or pressure in areas such as the face, limbs,
and chest.47 These events have been designated “triptan sensa-
tions” because they appear to occur with all sumatriptan-like
compounds developed to date. That these symptoms sometimes
occur in the chest has prompted concern among some prescribers
about the cardiovascular safety of triptans. Having undertaken a
comprehensive review of the pharmacologic and clinical data on
cardiovascular effects of triptans, a panel of experts convened in
2002 by the American Headache Society concluded that chest
symptoms occurring during use of triptans are generally nonse-
rious and are not explained by ischemia; the incidence of serious
cardiovascular events with triptans appears to be low, and the
cardiovascular risk-benefit profile of triptans favors their use in
the absence of contraindications.66 This assumption is strongly
supported by the results two published retrospective studies.67,68
In one of these studies, 13,664 of 63,575 (21.5%) migraine
patients were using a triptan. In the second of these studies,
50,383 of 130,411 (38.6%) were using a triptan. The use of
triptans was not associated with increased risk of any ischemic
events, including myocardial infarction and stroke, or mortality.
The most common adverse event in clinical studies of
sumatriptan conventional tablets was nausea, which is possibly
attributed to the migraine rather than to sumatriptan. In several
clinical studies, the adverse event profile of sumatriptan tablets
did not differ from that of placebo. Triptan sensations occur less
frequently with sumatriptan tablets than with the injection.
The most common adverse event in clinical trials of sumatrip-
tan nasal spray was a disturbance of taste, usually described as
bad, bitter, unpleasant, or unusual, and reported in about one
fourth of patients receiving sumatriptan nasal spray 20 mg.47
Other than disturbance of taste, adverse events with sumatriptan
nasal spray were reported at frequencies similar to those of
placebo.
The tolerability profile of the suppository was similar to that of
placebo in controlled clinical trials. Anorectal adverse events such
as burning, itching, or irritation were reported in less than 1% of
patients.
Contraindications
Myocardial infarction, ischemic heart disease, or experienced
coronary vasospasm; for review, see Dodick et al.66 Peripheral
vessel disease. Symptoms that indicate ischemic heart disease,
moderate-to-severe hypertension, disturbed liver function.
History of stroke or transient ischemic attack (TIA).
Pregnancy/nursing
There are no data to suggest teratogenicity for sumatriptan or any
of the other triptans,61,65 although data on the other triptans are
still limited; see, eg, Cassina et al.69
Methysergide-Pharmacodynamic and Pharmacokinetic
Properties
Methysergide (Fig. 4) is a potent antagonist at the 5-HT7 (and
5-HT2) receptor and an agonist at 5-HT1B, and, possibly, also
5-HT1D receptors (see Table 1). In vitro functional and radioli-
gand studies confirm that methysergide acts on 5-HT1B recep-
tors. Thus, methysergide contracts canine, bovine, and human
cerebral arteries, and the methysergide-induced contraction of
dog isolated saphenous vein is antagonized by the nonselective
5-HT1 and 5-HT2 receptor antagonist methiothepin but not by
the 5-HT2 receptor antagonist ketanserin.
The pharmacology of the metabolite methylergometrine has
been less investigated. However, it is a more potent vasoconstric-
tor than methysergide both in vivo and in vitro on, eg, canine
saphenous vein, and human basilar and coronary arteries.
The mechanism of action of methysergide in migraine is not
well understood. The efficacy of methysergide has been ascribed
Table 2.—Pharmacokinetic Characteristics of Sumatriptan Conventional Tablets, Nasal Spray, Injection, and Suppository47
Sumatriptan Tablets Sumatriptan Nasal Spray Sumatriptan Injection Sumatriptan Suppository
100 mg 20 mg 6 mg 25 mg
Maximum plasma
concentration (Cmax)
51 ng/mL 16 ng/mL 71 ng/mL 27 ng/mL
Time to Cmax (tmax) 2 hours 1-1.5 hours 12 minutes† 1.5 hours
Half-life (t1/2) 2.5 hours 2 hours 2 hours 1.8 hours
†After subcutaneous injection into the deltoid area of the arm.
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to its 5-HT2 receptor antagonist property. This is unlikely
because potent 5-HT2 receptor antagonists, such as mianserin,
sergolexole, ketanserin, and ICI 169,369, seem to be without any
prophylactic effect in migraine, and for cyproheptadine, the
claimed efficacy has never been confirmed in controlled clinical
trials.28 Therefore, it is highly improbable that 5-HT2 receptor
antagonism plays any role in migraine prophylaxis. Inhibition of
peptide release from perivascular sensory nerve endings as well as
neurogenic inflammation by methysergide, as demonstrated in
the rat, has also been invoked as a mechanism of action in
migraine. However, as argued elsewhere, there is considerable
doubt whether inhihition of neurogenic inflammation in
experimental animals is connected with antimigraine efficacy, as
several such compounds were found clinically ineffective in
migraine.
Formulations
Methysergide is only clinically available as a 1-mg tablet.
Adverse events
Retroperitoneal fibrosis, pleuropulmonary fibrosis, and fibrotic
thickening of cardiac valves may occur in patients receiving long-
term methysergide maleate therapy.30,31 Therefore, methysergide
must be reserved for prophylaxis in patients whose vascular head-
aches are frequent and/or severe and uncontrollable, and who are
under close medical supervision.
Contraindications
Contraindications to the use of methysergide include pregnancy,
peripheral vascular disorders, severe arteriosclerosis, coronary
artery disease, severe hypertension, thrombophlebitis or cellulitis
of the legs, peptic ulcer disease, liver or renal function impair-
ment, valvular heart disease, debilitation, or serious infection. As
mentioned earlier, all patients receiving methysergide should
remain under the supervision of the treating physician and be
examined regularly for the development of the rare pulmonary/
cardiac or peritoneal fibrosis, or the development of vascular
complications.31
Pregnancy/nursing
Methysergide should not be used during pregnancy.
SUMMARY AND CONCLUSIONS
Ergotamine, DHE, and methysergide have now been used in the
treatment of migraine for many decades, and there is some evi-
dence to support that their beneficial effects as antimigraine
agents are likely to result from the activation of 5-HT1B and
5-HT1D receptors.70 These findings led to the design and devel-
opment of sumatriptan, which was the first of a novel class of
drugs for the acute treatment of migraine, the so-called “trip-
tans.” Sumatriptan is a selective 5-HT1B/1D agonist, which lacks
effects at the other ergot sensitive monoamine receptors that can
mediate unwanted side effects like nausea, dysphoria, asthenia,
and vascular effects. DHE offers, however, several benefits com-
pared with ergotamine, including a lower incidence of nausea
and vomiting, and in comparison with sumatriptan lower head-
ache recurrence, and a lack of rebound headache. In particular,
DHE does not appear to be associated with 5-HT2B-induced
fibrosis that has been demonstrated for methysergide and
ergotamine.
Ergotamine, DHE, and sumatriptan are available in different
formulations of which the parenteral administration has been
demonstrated to be associated with a faster onset of action and
better efficacy. Appropriate use of their existing formulations
may increase the intraindividual consistency of response and
tolerability.
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